Liquid Biopsy Market Projected to Reach USD 15 Billion by 2030, Driven by Early Cancer Detection and Technological Advancements
According to Next Move Strategy Consulting, the global Liquid Biopsy Market is expected to reach USD 15 billion by 2030, growing at a compound annual growth rate (CAGR) of 16% by 2030. Liquid biopsy, a non-invasive diagnostic technique, enables the early detection and diagnosis of various cancers, including lung, liver, breast, and others. The procedure involves collecting blood samples to analyze tumor material such as DNA, RNA, and exosomes, offering valuable insights into tumor progression, therapeutic efficacy, and recurrence. This advanced diagnostic tool holds promise in improving patient outcomes through timely interventions and personalized treatments.
Download Free Sample: https://www.nextmsc.com/liquid-biopsy-market/request-sample
Market Dynamics and Growth Drivers
The liquid biopsy market is being propelled by the increasing prevalence of cancer globally, driven by risk factors such as high tobacco and alcohol consumption, poor dietary habits, and a growing aging population. Liquid biopsy offers significant benefits such as early diagnosis, monitoring of therapy efficacy, and detection of tumor heterogeneity, all without the need for invasive surgical procedures. These advantages are expected to further enhance the market's growth.
Advances in medical technology, particularly in digital polymerase chain reaction (dPCR) and next-generation sequencing (NGS), are anticipated to fuel market expansion. dPCR enhances the accuracy of liquid biopsy tests by breaking down nucleic acid samples into thousands of parallel PCR reactions, offering highly precise readings of DNA. Additionally, the emergence of NGS technology for the detection of rare ctDNA mutations further opens up opportunities for liquid biopsy, especially in early-stage cancer detection.
Challenges and Opportunities
Despite the promising growth prospects, the market faces challenges, including the high costs associated with research and development in clinical and laboratory settings. However, as next-generation sequencing technology continues to evolve, offering more targeted and sensitive mutation detection, the liquid biopsy market is expected to overcome these hurdles and unlock new growth avenues.
Inquire Before Buying: https://www.nextmsc.com/liquid-biopsy-market/inquire-before-buying
Market Segmentation and Scope
The liquid biopsy market is segmented across various categories, including product and service, cancer type, sampling type, circulating biomarker, technology, application, end user, and geography:
- Product and Service: Assay kits, instruments, reagents, and services
- Cancer Type: Lung, colorectal, breast, liver, prostate, and others
- Sampling Type: Blood sampling, urine sampling, saliva, and others
- Circulating Biomarker: Circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA, extracellular vesicles (EVs), and others
- Technology: Polymerase chain reaction (PCR), next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), and others
- Application: Cancer therapeutics, reproductive health, and other therapeutic applications
- End User: Reference laboratories, hospitals, academic and research centers, and others
Geographical Insights
North America holds the largest share of the liquid biopsy market, a position that is expected to continue through the forecast period. The region benefits from high adoption of liquid biopsy techniques in hospitals, academic research centers, and diagnostic laboratories. For example, in July 2022, BillionToOne Inc. launched oncology liquid biopsy products and collaborated with the University of California San Diego to advance clinical research.
In contrast, the Asia-Pacific region is showing steady growth in the liquid biopsy market, driven by government funding for cancer treatment and an increase in diagnostic laboratories. In 2022, the Australian government allocated USD 893.5 million to enhance cancer treatment and survival rates, further fueling market growth. The rising preference for non-invasive diagnostic methods among cancer patients in the region is also contributing to the market’s expansion.
Competitive Landscape
Leading players in the liquid biopsy market include Bio-Rad Laboratories Inc., Biocept Inc., BillionToOne Inc., F. Hoffmann-La Roche Ltd., Qiagen N.V., Myriad Genetics, Thermo Fisher Scientific Inc., Guardant Health Inc., MDX Health SA., and Artemis DNA Inc. These companies are actively expanding their market presence through regulatory approvals, strategic partnerships, and collaborations.
For instance, in March 2022, Guardant Health received Japanese regulatory approval for its Guardant360 CDx liquid biopsy test, marking a significant milestone in the adoption of liquid biopsy in Japan. Similarly, Artemis DNA, Inc. entered into a partnership with Datar Cancer Genetics, resulting in a USD 250 million contract to distribute revolutionary liquid biopsy tests in the USA and Vietnam.
Conclusion
The liquid biopsy market is poised for substantial growth over the next decade, driven by rising cancer prevalence, technological advancements, and increasing adoption of non-invasive diagnostic methods. While challenges such as high research and development costs remain, the market offers significant opportunities through innovations in sequencing technologies and a growing focus on personalized medicine.
Also, Browse Related Reports:
For more information, please contact:
Next Move Strategy Consulting
E-Mail: info@nextmsc.com
Direct: +1-217-650-7991
Website: www.nextmsc.com
Follow Us: LinkedIn | Twitter | Facebook | Instagram | YouTube
About Next Move Strategy Consulting:
Next Move Strategy Consulting is a premier market research and management consulting firm that has been committed to provide strategically analysed well documented latest research reports to its clients. The research industry is flooded with many firms to choose from, what makes Next Move different from the rest is its top-quality research and the obsession of turning data into knowledge by dissecting every bit of it and providing fact-based research recommendation that is supported by information collected from over 500 million websites, paid databases, industry journals and one on one consultations with industry experts across a diverse range of industry sectors. The high-quality customized research reports with actionable insights and excellent end-to-end customer service help our clients to take critical business decisions that enables them to move beyond time and have competitive edge in the industry.
We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicates as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solutions that range from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.